{"id":344884,"date":"2025-08-24T14:17:57","date_gmt":"2025-08-24T14:17:57","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-ab-science-sa\/"},"modified":"2025-08-24T14:17:57","modified_gmt":"2025-08-24T14:17:57","slug":"how-to-buy-ab-science-sa","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/","title":{"rendered":"How to buy AB Science S.A. (AB) shares &#8211; Investment in AB Science S.A. (AB) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334099,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-344884","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy AB Science S.A. (AB) Shares - Investment in AB Science S.A. (AB) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy AB Science S.A. (AB) Shares - Investment in AB Science S.A. (AB) Stock"},"description":"Learn how to buy AB Science S.A. (AB) shares with our comprehensive investment analysis covering current price, risks, and growth potential for 2025-2030.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to buy AB Science S.A. (AB) shares with our comprehensive investment analysis covering current price, risks, and growth potential for 2025-2030."},"intro":"Thinking about investing in cutting-edge biotech innovation? AB Science S.A. represents the thrilling world of pharmaceutical development where clinical breakthroughs can transform patient lives\u2014and investor portfolios. This French biopharma company specializes in kinase inhibitors for cancer and inflammatory diseases, offering both significant risks and extraordinary potential rewards for savvy investors.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in cutting-edge biotech innovation? AB Science S.A. represents the thrilling world of pharmaceutical development where clinical breakthroughs can transform patient lives\u2014and investor portfolios. This French biopharma company specializes in kinase inhibitors for cancer and inflammatory diseases, offering both significant risks and extraordinary potential rewards for savvy investors."},"body_html":"<h2>\ud83d\udcc8 AB Science Stock: Current Price and Market Position<\/h2> <p>As of August 24, 2025, AB Science S.A. (AB.PA) trades at <strong>1.29\u20ac<\/strong> on Euronext Paris. The company carries a market capitalization of approximately 79.24 million euros, placing it firmly in the micro-cap category\u2014perfect for investors seeking high-growth opportunities with corresponding risk levels.<\/p> <p><strong>Critical Date Alert: September 30, 2025<\/strong> marks the company's next earnings release. Historical patterns show these events typically trigger significant price movements. The previous earnings report on May 9, 2025, followed a pattern where positive clinical trial news has previously driven substantial gains.<\/p> <h3>Recent Price Performance Analysis<\/h3> <table> <thead> <tr><th>Date<\/th><th>Price Movement<\/th><th>Key Catalyst<\/th><\/tr> <\/thead> <tbody> <tr><td>February 2025<\/td><td>+74% surge<\/td><td>Positive clinical trial data anticipation<\/td><\/tr> <tr><td>May 2025<\/td><td>Capital increase settlement<\/td><td>\u20ac1.8 million funding secured<\/td><\/tr> <tr><td>July 2025<\/td><td>Private placement completion<\/td><td>Additional \u20ac1.925 million raised<\/td><\/tr> <tr><td>August 2025<\/td><td>Recent capital raise<\/td><td>\u20ac2.55 million funding injection<\/td><\/tr> <\/tbody> <\/table> <p>The stock has shown a <strong>31.63% annual gain<\/strong> despite recent monthly pressure showing a <strong>-7.06% decline<\/strong>, reflecting the bipolar nature of biotech investing where long-term optimism battles short-term volatility.<\/p>  [cta_green text=\"Start trading\"]<h2>\ud83c\udfaf Strategic Entry Points: Earnings Impact Analysis<\/h2> <p>Mark your calendar for <strong>September 29, 2025<\/strong>\u2014this represents the next major potential volatility catalyst when AB Science releases its half-year results. Historical earnings reactions show patterns worth noting:<\/p> <p>Recent clinical trial authorization news in July 2025 created positive momentum, similar to February's 74% surge following regulatory approvals. The company's successful capital raises throughout 2025 (totaling over \u20ac6 million) demonstrate continued investor confidence despite sector-wide funding challenges.<\/p>  <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <p>Based on current analyst consensus and clinical development trajectory:<\/p> <ul> <li><strong>2025 Year-End Target: 2.50-3.00\u20ac<\/strong> (93-132% upside) <ul> <li>Driven by masitinib Phase 3 trial progress<\/li> <li>Potential positive interim data releases<\/li> <li>Continued successful fundraising<\/li> <\/ul> <\/li> <li><strong>2026 Projection: 3.50-4.50\u20ac<\/strong> <ul> <li>Possible FDA breakthrough therapy designation<\/li> <li>Expansion into additional cancer indications<\/li> <li>Partnership opportunities with major pharma<\/li> <\/ul> <\/li> <li><strong>2028 Outlook: 6.00-8.00\u20ac<\/strong> <ul> <li>Potential first commercial approvals<\/li> <li>Revenue generation from licensed territories<\/li> <li>Pipeline expansion beyond masitinib<\/li> <\/ul> <\/li> <li><strong>2030 Vision: 10.00\u20ac+<\/strong> <ul> <li>Established commercial presence<\/li> <li>Multiple approved indications<\/li> <li>Sustainable revenue growth<\/li> <\/ul> <\/li> <\/ul> <p><strong>Current Verdict: STRONG BUY<\/strong> for risk-tolerant investors<br> The average analyst price target of 3.53\u20ac represents 173% potential upside, making current levels attractive for long-term positioning.<\/p>  <h2>\u26a0\ufe0f Risk Assessment: Navigating Biotech Volatility<\/h2> <h3>High-Risk Factors<\/h3> <ul> <li><strong>Clinical Trial Dependency<\/strong>: Masitinib's success determines company valuation<\/li> <li><strong>Funding Vulnerability<\/strong>: Biotech sector facing 57% funding drop in 2025<\/li> <li><strong>Regulatory Uncertainty<\/strong>: FDA approval timelines remain unpredictable<\/li> <li><strong>Binary Outcomes<\/strong>: Single trial result can cause 20-30% daily moves<\/li> <\/ul> <h3>Positive Catalysts for 2025<\/h3> <ul> <li><strong>Dual Regulatory Approvals<\/strong>: FDA and EMA greenlit Phase 3 trials for both ALS and prostate cancer<\/li> <li><strong>Successful Fundraising<\/strong>: \u20ac6+ million raised in 2025 ensures runway extension<\/li> <li><strong>Industry Tailwinds<\/strong>: Aging population driving oncology demand growth<\/li> <li><strong>Analyst Support<\/strong>: 9 covering analysts with average 3.53\u20ac target price<\/li> <\/ul>  <h2>\ud83d\udcca Recent Major News Impact Analysis<\/h2> <p>July 2025 proved transformational for AB Science with two major regulatory victories:<\/p> <p><strong>July 4, 2025<\/strong>: <a href=\"https:\/\/www.biospace.com\/press-releases\/ab-science-masitinib-receives-fda-and-ema-authorization-for-confirmatory-phase-3-trial-in-metastatic-castrate-resistant-prostate-cancer\">FDA and EMA simultaneously authorized<\/a> Phase 3 trial for metastatic prostate cancer\u2014the first potential targeted combination with docetaxel in nearly two decades.<\/p> <p><strong>July 24, 2025<\/strong>: <a href=\"https:\/\/www.biospace.com\/press-releases\/ab-science-has-received-approval-from-several-european-countries-to-initiate-the-confirmatory-phase-3-study-of-masitinib-in-als\">European countries approved<\/a> Phase 3 ALS study initiation, completing both CTIS procedure steps.<\/p> <p>These approvals validate masitinib's mechanism across multiple indications, significantly de-risking the investment thesis while maintaining substantial upside potential.<\/p>  <h2>\ud83d\udee1\ufe0f Beginner Trader Action Plan Today<\/h2> <ol> <li><strong>Position Sizing<\/strong>: Allocate no more than 2-5% of portfolio to high-risk biotech<\/li> <li><strong>Dollar-Cost Average<\/strong>: Accumulate shares gradually before September earnings<\/li> <li><strong>Stop-Loss Protection<\/strong>: Set 15-20% stop losses to manage volatility risk<\/li> <li><strong>Catalyst Calendar<\/strong>: Mark September 30 earnings and clinical trial milestones<\/li> <\/ol> <p><em>Humorous veteran insight: \"Trading AB Science is like watching clinical trials\u201490% boredom waiting for results, 10% sheer terror when they arrive. Bring extra coffee and antacids!\"<\/em><\/p>  <h2>\u2705 How to Buy AB Science S.A. (AB) Shares - Step by Step<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Select trading platform<\/td><td>Ensure Euronext Paris access for AB.PA listing<\/td><\/tr> <tr><td>2<\/td><td>Complete account funding<\/td><td>Start with small position given high volatility<\/td><\/tr> <tr><td>3<\/td><td>Search \"AB.PA\" ticker<\/td><td>Use correct exchange-specific identifier<\/td><\/tr> <tr><td>4<\/td><td>Choose limit order type<\/td><td>Set maximum entry price to avoid slippage<\/td><\/tr> <tr><td>5<\/td><td>Execute purchase<\/td><td>Confirm low commission rates (&lt;0.5%)<\/td><\/tr> <tr><td>6<\/td><td>Set price alerts<\/td><td>Monitor for earnings volatility opportunities<\/td><\/tr> <tr><td>7<\/td><td>Document investment thesis<\/td><td>Note key clinical catalysts and timelines<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Why Pocket Option Excels for Biotech Investing<\/h2> <p>Pocket Option offers unique advantages for navigating volatile biotech stocks like AB Science:<\/p> <ul> <li><strong>Minimum deposit of $5<\/strong> allows testing investment theses with minimal risk exposure\u2014crucial when dealing with binary-outcome stocks where 20% daily moves are common.<\/li> <li><strong>Rapid verification process<\/strong> means you can capitalize on breaking news immediately when clinical trial results or regulatory decisions hit the wires.<\/li> <li><strong>Diverse withdrawal options<\/strong> ensure you can quickly secure profits during volatility spikes that often follow positive clinical data releases.<\/li> <\/ul>  <h2>\ud83c\udf0d AB Science in 2025: Clinical Innovation Leader<\/h2> <p>AB Science stands at the forefront of personalized medicine with its kinase inhibitor platform. The company's strategic shift to biomarker-driven patient selection represents the future of targeted cancer therapy. Current market position reflects a typical clinical-stage biotech\u2014burning cash while advancing promising compounds through late-stage trials.<\/p> <p><strong>2025 Interesting Fact<\/strong>: AB Science achieved something rare in biotech\u2014simultaneous FDA and EMA approval for Phase 3 trials in July 2025, a testament to their robust clinical data and regulatory strategy across both major pharmaceutical markets.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 AB Science Stock: Current Price and Market Position<\/h2>\n<p>As of August 24, 2025, AB Science S.A. (AB.PA) trades at <strong>1.29\u20ac<\/strong> on Euronext Paris. The company carries a market capitalization of approximately 79.24 million euros, placing it firmly in the micro-cap category\u2014perfect for investors seeking high-growth opportunities with corresponding risk levels.<\/p>\n<p><strong>Critical Date Alert: September 30, 2025<\/strong> marks the company&#8217;s next earnings release. Historical patterns show these events typically trigger significant price movements. The previous earnings report on May 9, 2025, followed a pattern where positive clinical trial news has previously driven substantial gains.<\/p>\n<h3>Recent Price Performance Analysis<\/h3>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Price Movement<\/th>\n<th>Key Catalyst<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>February 2025<\/td>\n<td>+74% surge<\/td>\n<td>Positive clinical trial data anticipation<\/td>\n<\/tr>\n<tr>\n<td>May 2025<\/td>\n<td>Capital increase settlement<\/td>\n<td>\u20ac1.8 million funding secured<\/td>\n<\/tr>\n<tr>\n<td>July 2025<\/td>\n<td>Private placement completion<\/td>\n<td>Additional \u20ac1.925 million raised<\/td>\n<\/tr>\n<tr>\n<td>August 2025<\/td>\n<td>Recent capital raise<\/td>\n<td>\u20ac2.55 million funding injection<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The stock has shown a <strong>31.63% annual gain<\/strong> despite recent monthly pressure showing a <strong>-7.06% decline<\/strong>, reflecting the bipolar nature of biotech investing where long-term optimism battles short-term volatility.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83c\udfaf Strategic Entry Points: Earnings Impact Analysis<\/h2>\n<p>Mark your calendar for <strong>September 29, 2025<\/strong>\u2014this represents the next major potential volatility catalyst when AB Science releases its half-year results. Historical earnings reactions show patterns worth noting:<\/p>\n<p>Recent clinical trial authorization news in July 2025 created positive momentum, similar to February&#8217;s 74% surge following regulatory approvals. The company&#8217;s successful capital raises throughout 2025 (totaling over \u20ac6 million) demonstrate continued investor confidence despite sector-wide funding challenges.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<p>Based on current analyst consensus and clinical development trajectory:<\/p>\n<ul>\n<li><strong>2025 Year-End Target: 2.50-3.00\u20ac<\/strong> (93-132% upside)\n<ul>\n<li>Driven by masitinib Phase 3 trial progress<\/li>\n<li>Potential positive interim data releases<\/li>\n<li>Continued successful fundraising<\/li>\n<\/ul>\n<\/li>\n<li><strong>2026 Projection: 3.50-4.50\u20ac<\/strong>\n<ul>\n<li>Possible FDA breakthrough therapy designation<\/li>\n<li>Expansion into additional cancer indications<\/li>\n<li>Partnership opportunities with major pharma<\/li>\n<\/ul>\n<\/li>\n<li><strong>2028 Outlook: 6.00-8.00\u20ac<\/strong>\n<ul>\n<li>Potential first commercial approvals<\/li>\n<li>Revenue generation from licensed territories<\/li>\n<li>Pipeline expansion beyond masitinib<\/li>\n<\/ul>\n<\/li>\n<li><strong>2030 Vision: 10.00\u20ac+<\/strong>\n<ul>\n<li>Established commercial presence<\/li>\n<li>Multiple approved indications<\/li>\n<li>Sustainable revenue growth<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><strong>Current Verdict: STRONG BUY<\/strong> for risk-tolerant investors<br \/> The average analyst price target of 3.53\u20ac represents 173% potential upside, making current levels attractive for long-term positioning.<\/p>\n<h2>\u26a0\ufe0f Risk Assessment: Navigating Biotech Volatility<\/h2>\n<h3>High-Risk Factors<\/h3>\n<ul>\n<li><strong>Clinical Trial Dependency<\/strong>: Masitinib&#8217;s success determines company valuation<\/li>\n<li><strong>Funding Vulnerability<\/strong>: Biotech sector facing 57% funding drop in 2025<\/li>\n<li><strong>Regulatory Uncertainty<\/strong>: FDA approval timelines remain unpredictable<\/li>\n<li><strong>Binary Outcomes<\/strong>: Single trial result can cause 20-30% daily moves<\/li>\n<\/ul>\n<h3>Positive Catalysts for 2025<\/h3>\n<ul>\n<li><strong>Dual Regulatory Approvals<\/strong>: FDA and EMA greenlit Phase 3 trials for both ALS and prostate cancer<\/li>\n<li><strong>Successful Fundraising<\/strong>: \u20ac6+ million raised in 2025 ensures runway extension<\/li>\n<li><strong>Industry Tailwinds<\/strong>: Aging population driving oncology demand growth<\/li>\n<li><strong>Analyst Support<\/strong>: 9 covering analysts with average 3.53\u20ac target price<\/li>\n<\/ul>\n<h2>\ud83d\udcca Recent Major News Impact Analysis<\/h2>\n<p>July 2025 proved transformational for AB Science with two major regulatory victories:<\/p>\n<p><strong>July 4, 2025<\/strong>: <a href=\"https:\/\/www.biospace.com\/press-releases\/ab-science-masitinib-receives-fda-and-ema-authorization-for-confirmatory-phase-3-trial-in-metastatic-castrate-resistant-prostate-cancer\">FDA and EMA simultaneously authorized<\/a> Phase 3 trial for metastatic prostate cancer\u2014the first potential targeted combination with docetaxel in nearly two decades.<\/p>\n<p><strong>July 24, 2025<\/strong>: <a href=\"https:\/\/www.biospace.com\/press-releases\/ab-science-has-received-approval-from-several-european-countries-to-initiate-the-confirmatory-phase-3-study-of-masitinib-in-als\">European countries approved<\/a> Phase 3 ALS study initiation, completing both CTIS procedure steps.<\/p>\n<p>These approvals validate masitinib&#8217;s mechanism across multiple indications, significantly de-risking the investment thesis while maintaining substantial upside potential.<\/p>\n<h2>\ud83d\udee1\ufe0f Beginner Trader Action Plan Today<\/h2>\n<ol>\n<li><strong>Position Sizing<\/strong>: Allocate no more than 2-5% of portfolio to high-risk biotech<\/li>\n<li><strong>Dollar-Cost Average<\/strong>: Accumulate shares gradually before September earnings<\/li>\n<li><strong>Stop-Loss Protection<\/strong>: Set 15-20% stop losses to manage volatility risk<\/li>\n<li><strong>Catalyst Calendar<\/strong>: Mark September 30 earnings and clinical trial milestones<\/li>\n<\/ol>\n<p><em>Humorous veteran insight: &#8220;Trading AB Science is like watching clinical trials\u201490% boredom waiting for results, 10% sheer terror when they arrive. Bring extra coffee and antacids!&#8221;<\/em><\/p>\n<h2>\u2705 How to Buy AB Science S.A. (AB) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Select trading platform<\/td>\n<td>Ensure Euronext Paris access for AB.PA listing<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete account funding<\/td>\n<td>Start with small position given high volatility<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Search &#8220;AB.PA&#8221; ticker<\/td>\n<td>Use correct exchange-specific identifier<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Choose limit order type<\/td>\n<td>Set maximum entry price to avoid slippage<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Execute purchase<\/td>\n<td>Confirm low commission rates (&lt;0.5%)<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Set price alerts<\/td>\n<td>Monitor for earnings volatility opportunities<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Document investment thesis<\/td>\n<td>Note key clinical catalysts and timelines<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Excels for Biotech Investing<\/h2>\n<p>Pocket Option offers unique advantages for navigating volatile biotech stocks like AB Science:<\/p>\n<ul>\n<li><strong>Minimum deposit of $5<\/strong> allows testing investment theses with minimal risk exposure\u2014crucial when dealing with binary-outcome stocks where 20% daily moves are common.<\/li>\n<li><strong>Rapid verification process<\/strong> means you can capitalize on breaking news immediately when clinical trial results or regulatory decisions hit the wires.<\/li>\n<li><strong>Diverse withdrawal options<\/strong> ensure you can quickly secure profits during volatility spikes that often follow positive clinical data releases.<\/li>\n<\/ul>\n<h2>\ud83c\udf0d AB Science in 2025: Clinical Innovation Leader<\/h2>\n<p>AB Science stands at the forefront of personalized medicine with its kinase inhibitor platform. The company&#8217;s strategic shift to biomarker-driven patient selection represents the future of targeted cancer therapy. Current market position reflects a typical clinical-stage biotech\u2014burning cash while advancing promising compounds through late-stage trials.<\/p>\n<p><strong>2025 Interesting Fact<\/strong>: AB Science achieved something rare in biotech\u2014simultaneous FDA and EMA approval for Phase 3 trials in July 2025, a testament to their robust clinical data and regulatory strategy across both major pharmaceutical markets.<\/p>\n"},"faq":[{"question":"What is AB Science's main drug candidate?","answer":"Masitinib is their lead compound, currently in Phase 3 trials for ALS and metastatic prostate cancer with biomarker-driven patient selection."},{"question":"How often does AB Science release earnings reports?","answer":"The company reports semi-annually, with next results scheduled for September 30, 2025."},{"question":"What percentage of my portfolio should I allocate to AB Science?","answer":"Given the high risk profile, conservative investors should limit exposure to 1-2%, while aggressive investors might allocate 5-10%."},{"question":"How do clinical trial results typically affect the stock price?","answer":"Positive results can drive 50-100% gains in days, while negative results often cause 30-70% declines\u2014classic biotech volatility."},{"question":"What is the company's cash runway situation?","answer":"Successful 2025 fundraising (\u20ac6+ million) provides adequate runway for ongoing trials, reducing near-term dilution risk."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"What is AB Science's main drug candidate?","answer":"Masitinib is their lead compound, currently in Phase 3 trials for ALS and metastatic prostate cancer with biomarker-driven patient selection."},{"question":"How often does AB Science release earnings reports?","answer":"The company reports semi-annually, with next results scheduled for September 30, 2025."},{"question":"What percentage of my portfolio should I allocate to AB Science?","answer":"Given the high risk profile, conservative investors should limit exposure to 1-2%, while aggressive investors might allocate 5-10%."},{"question":"How do clinical trial results typically affect the stock price?","answer":"Positive results can drive 50-100% gains in days, while negative results often cause 30-70% declines\u2014classic biotech volatility."},{"question":"What is the company's cash runway situation?","answer":"Successful 2025 fundraising (\u20ac6+ million) provides adequate runway for ongoing trials, reducing near-term dilution risk."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy AB Science S.A. (AB) shares - Investment in AB Science S.A. (AB) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy AB Science S.A. (AB) shares - Investment in AB Science S.A. (AB) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-24T14:17:57+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy AB Science S.A. (AB) shares &#8211; Investment in AB Science S.A. (AB) stock\",\"datePublished\":\"2025-08-24T14:17:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/\",\"name\":\"How to buy AB Science S.A. (AB) shares - Investment in AB Science S.A. (AB) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"datePublished\":\"2025-08-24T14:17:57+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy AB Science S.A. (AB) shares &#8211; Investment in AB Science S.A. (AB) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy AB Science S.A. (AB) shares - Investment in AB Science S.A. (AB) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/","og_locale":"en_US","og_type":"article","og_title":"How to buy AB Science S.A. (AB) shares - Investment in AB Science S.A. (AB) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-24T14:17:57+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy AB Science S.A. (AB) shares &#8211; Investment in AB Science S.A. (AB) stock","datePublished":"2025-08-24T14:17:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/","name":"How to buy AB Science S.A. (AB) shares - Investment in AB Science S.A. (AB) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","datePublished":"2025-08-24T14:17:57+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-ab-science-sa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy AB Science S.A. (AB) shares &#8211; Investment in AB Science S.A. (AB) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":344946,"slug":"how-to-buy-ab-science-sa","post_title":"Comment acheter des actions AB Science S.A. (AB) - Investissement dans les actions AB Science S.A. (AB)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-ab-science-sa\/"},"it_IT":{"locale":"it_IT","id":344939,"slug":"how-to-buy-ab-science-sa","post_title":"Come acquistare azioni AB Science S.A. (AB) - Investire in azioni AB Science S.A. (AB)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-ab-science-sa\/"},"pl_PL":{"locale":"pl_PL","id":344945,"slug":"how-to-buy-ab-science-sa","post_title":"Jak kupi\u0107 akcje AB Science S.A. (AB) - Inwestycja w akcje AB Science S.A. (AB)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-ab-science-sa\/"},"es_ES":{"locale":"es_ES","id":344942,"slug":"how-to-buy-ab-science-sa","post_title":"C\u00f3mo comprar acciones de AB Science S.A. (AB) - Inversi\u00f3n en acciones de AB Science S.A. (AB)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-ab-science-sa\/"},"th_TH":{"locale":"th_TH","id":344947,"slug":"how-to-buy-ab-science-sa","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 AB Science S.A. (AB) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 AB Science S.A. (AB)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-ab-science-sa\/"},"tr_TR":{"locale":"tr_TR","id":344948,"slug":"how-to-buy-ab-science-sa","post_title":"AB Science S.A. (AB) Hisseleri Nas\u0131l Al\u0131n\u0131r - AB Science S.A. (AB) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ab-science-sa\/"},"vt_VT":{"locale":"vt_VT","id":344941,"slug":"how-to-buy-ab-science-sa","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu AB Science S.A. (AB) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu AB Science S.A. (AB)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-ab-science-sa\/"},"pt_AA":{"locale":"pt_AA","id":344940,"slug":"how-to-buy-ab-science-sa","post_title":"Como comprar a\u00e7\u00f5es da AB Science S.A. (AB) - Investimento em a\u00e7\u00f5es da AB Science S.A. (AB)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-ab-science-sa\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/344884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=344884"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/344884\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334099"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=344884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=344884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=344884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}